Afatinib* has been investigated in two Phase III trials in patients with head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy. The rationale for these studies is that there is no well-defined standard of care and few efficacious treatment options for patients in this setting.
You can find out more about the clinical trials of afatinib in this setting using the links below.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.